CXCR4 Antagonist in HPV5-Associated Perianal Squamous-Cell Carcinoma

This correspondence details a case study of a 29 year old man with WHIM like syndrome treated with the CXCR4 antagonist plerixafor. The patient presented with HPV5-associated perianal squamous-cell carcinoma and profound panleukopenia. Six months of plerixafor therapy, alongside short term imiquimod, led to complete regression of the carcinoma and restoration of dendritic-cell levels. After six years off treatment, the carcinoma recurred, reinforcing the potential of long term CXCR4 targeted therapy in immunocompromised patients.

This correspondence details a case study of a 29 year old man with WHIM like syndrome treated with the CXCR4 antagonist plerixafor. The patient presented with HPV5-associated perianal squamous-cell carcinoma and profound panleukopenia. Six months of plerixafor therapy, alongside short term imiquimod, led to complete regression of the carcinoma and restoration of dendritic-cell levels. After six years off treatment, the carcinoma recurred, reinforcing the potential of long term CXCR4 targeted therapy in immunocompromised patients.